Literature DB >> 29501586

PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.

Luping Wang1, Zhuoming Li1, Yinzi Tan2, Qian Li1, Hanwei Yang1, Panxia Wang1, Jing Lu3, Peiqing Liu4.   

Abstract

The activation of signal transducer and activator of transcription 3 (STAT3) positively regulates myocardial hypertrophy, and its transcriptional activity is finely conditioned by diverse extracellular growth factors and cytokines. Here, we introduce novel evidence that poly(ADP-ribose) polymerase 1 (PARP1) interacts with STAT3 and promotes its activation in cardiomyocytes and rat heart tissues. PARP1 activity and phosphorylated STAT3 were augmented by hypertrophic stimuli both in vitro and in vivo. Infection of PARP1 adenovirus induced cardiomyocyte hypertrophy, which could be prevented by STAT3 knockdown or inhibition. Additionally, PARP1 enhanced STAT3 phosphorylation level, nuclear accumulation and transcriptional activity. Mechanistically, PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus. In conclusion, our findings provide the first evidence that PARP1 exacerbates cardiac hypertrophy by stabilizing active phosphorylated-STAT3, which suggests that multi-target therapeutic strategies counteracting PARP1 activity and STAT3 activation would be potential for treating cardiovascular diseases.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Heart; PARP1; STAT3

Mesh:

Substances:

Year:  2018        PMID: 29501586     DOI: 10.1016/j.mce.2018.02.020

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

1.  Identification of a Hydrogen-Sulfide-Releasing Isochroman-4-One Hybrid as a Cardioprotective Candidate for the Treatment of Cardiac Hypertrophy.

Authors:  Yu Wang; Yuechen Liu; Hongyu Wu; Shengtao Xu; Fenfen Ma
Journal:  Molecules       Date:  2022-06-27       Impact factor: 4.927

2.  Sorting nexin 3 induces heart failure via promoting retromer-dependent nuclear trafficking of STAT3.

Authors:  Jing Lu; Suowen Xu; Yuqing Huo; Duanping Sun; Yuehuai Hu; Junjian Wang; Xiaolei Zhang; Panxia Wang; Zhuoming Li; Mengya Liang; Zhongkai Wu; Peiqing Liu
Journal:  Cell Death Differ       Date:  2021-05-04       Impact factor: 12.067

3.  CXCR2 expression on granulocyte and macrophage progenitors under tumor conditions contributes to mo-MDSC generation via SAP18/ERK/STAT3.

Authors:  Xiaoqing Han; Huifang Shi; Yingying Sun; Chao Shang; Tao Luan; Dake Wang; Xueqing Ba; Xianlu Zeng
Journal:  Cell Death Dis       Date:  2019-08-08       Impact factor: 8.469

Review 4.  Recent Developments on the Crosstalk Between STAT3 and Inflammation in Heart Function and Disease.

Authors:  Mazen Kurdi; Carlos Zgheib; George W Booz
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

Review 5.  The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors.

Authors:  Maciej Sobczak; Marharyta Zyma; Agnieszka Robaszkiewicz
Journal:  Cells       Date:  2020-09-06       Impact factor: 6.600

6.  The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy.

Authors:  Luping Wang; Panxia Wang; Suowen Xu; Zhuoming Li; Dayue Darrel Duan; Jiantao Ye; Jingyan Li; Yanqing Ding; Wenqing Zhang; Jing Lu; Peiqing Liu
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

7.  The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy.

Authors:  Zhenzhen Li; Zhen Guo; Rui Lan; Sidong Cai; Zhirong Lin; Jingyan Li; Junjian Wang; Zhuoming Li; Peiqing Liu
Journal:  Acta Pharm Sin B       Date:  2020-12-14       Impact factor: 11.413

8.  Schisandrin Protects against Norepinephrine-Induced Myocardial Hypertrophic Injury by Inhibiting the JAK2/STAT3 Signaling Pathway.

Authors:  Min Yang; Xing-Can Jiang; Lei Wang; Dong-An Cui; Jing-Yan Zhang; Xu-Rong Wang; Hai-Peng Feng; Kang Zhang; Kai Zhang; Jian-Xi Li; Xue-Zhi Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-16       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.